300 related articles for article (PubMed ID: 22778320)
1. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA; Stuart K; Earle CC; Clark JW; Bhargava P; Miksad R; Blaszkowsky L; Enzinger PC; Meyerhardt JA; Zheng H; Fuchs CS; Kulke MH
J Clin Oncol; 2012 Aug; 30(24):2963-8. PubMed ID: 22778320
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
[TBL] [Abstract][Full Text] [Related]
3. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Zhao J; Zhao H; Chi Y
Neuroendocrinology; 2018; 106(4):318-323. PubMed ID: 28817826
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
7. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
12. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Cheng YJ; Meng CT; Ying HY; Zhou JF; Yan XY; Gao X; Zhou N; Bai CM
Medicine (Baltimore); 2018 Nov; 97(45):e12750. PubMed ID: 30407280
[TBL] [Abstract][Full Text] [Related]
13. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
Bajetta E; Rimassa L; Carnaghi C; Seregni E; Ferrari L; Di Bartolomeo M; Regalia E; Cassata A; Procopio G; Mariani L
Cancer; 1998 Jul; 83(2):372-8. PubMed ID: 9669822
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
16. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN
Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053
[TBL] [Abstract][Full Text] [Related]
20. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Kulke MH; Chan JA; Meyerhardt JA; Zhu AX; Abrams TA; Blaszkowsky LS; Regan E; Sidor C; Fuchs CS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):293-300. PubMed ID: 20960192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]